We Wonder if Someone Gets a Commission on That | GenomeWeb

GlaxoSmithKline must have been feeling generous: the pharma gave $25 million to the Harvard Stem Cell Institute for a five-year partnership "to develop new methods for screening drugs with stem cells," according to this news item from Technology Review. "The time appears ripe for investing, because scientists can now use new reprogramming techniques to develop stem cells from patients with specific diseases."

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.